Philippe Duchâteau

Cellecta (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

41h-index6.8kcitations120works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(59), CAR-T cell therapy research(41), RNA Interference and Gene Delivery(21), Virus-based gene therapy research(17), Viral Infectious Diseases and Gene Expression in Insects(17)

Publications120 total

Supplementary Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2025Open Access
Circular single stranded DNA potentiates non-viral gene insertion in hematopoietic stem and progenitor cells
Nature Communications·2025Open Access
Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing
2025· 1 citedOpen Access
Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer
Science Advances·2024· 26 citedOpen Access
TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity
Molecular Therapy·2024· 24 citedOpen Access
Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells
Nature Communications·2024· 18 citedOpen Access
Comprehensive analysis of the editing window of C-to-T TALE base editors
Scientific Reports·2024· 2 citedOpen Access
TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage
Molecular Therapy·2024· 4 citedOpen Access
TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage
2024Open Access
Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction
Molecular Therapy — Methods & Clinical Development·2023· 4 citedOpen Access
Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Supplementary Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Supplementary Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Supplementary Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
Cancer Immunology Research·2023· 9 citedOpen Access
Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Supplementary Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
2023Open Access
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
Frontiers in Immunology·2023· 44 citedOpen Access
Gene Editing/Gene Therapies: UCART20X22: ALLOGENEIC DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
Cytotherapy·2023
page 1 of 6Next →

Frequent Co-authors

Frédéric Pâques(17), Laurent Poirot(14), Aymeric Duclert(14), Julien Valton(14), Alexandre Juillerat(13), Fayza Daboussi(10), Valérie Guyot(10), Julianne Smith(9), Guillermo Montoya(8), John P. Kane(8), Alan Maréchal(7), Román Galetto(7), Sylvestre Grizot(7), Agnès Gouble(7), Jean-Charles Epinat(6), Jesús Prìeto(6), Francisco J. Blanco(6), Christophe Perez(6), Sophie Leduc(5), Sylvain Arnould(5)